|
1
|
Antoni S, Ferlay J, Soerjomataram I, Znaor
A, Jemal A and Bray F: Bladder cancer incidence and mortality: A
global overview and recent trends. Eur Urol. 71:96–108. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pinto IG: Systemic therapy in bladder
cancer. Indian J Urol. 33:118–126. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Burger M, Catto JW, Dalbagni G, Grossman
HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C,
Shariat S and Lotan Y: Epidemiology and risk factors of urothelial
bladder cancer. Eur Urol. 63:234–241. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Choueiri TK and Raghavan D: Chemotherapy
for muscle-invasive bladder cancer treated with definitive
radiotherapy: Persisting uncertainties. Nat Clin Pract Oncol.
5:444–454. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Forbes SA, Bindal N, Bamford S, Cole C,
Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, et al:
COSMIC: Mining complete cancer genomes in the catalogue of somatic
mutations in cancer. Nucleic Acids Res. 39:(Database Issue).
D945–D950. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Goebell PJ and Knowles MA: Bladder cancer
or bladder cancers? Genetically distinct malignant conditions of
the urothelium. Urol Oncol. 28:409–428. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cancer Genome Atlas Research Network:
Comprehensive molecular characterization of urothelial bladder
carcinoma. Nature. 507:315–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guo W, Xie L, Zhao L and Zhao Y: mRNA and
microRNA expression profiles of radioresistant NCI-H520 non-small
celllung cancer cells. Mol Med Rep. 12:1857–1867. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mengual L, Burset M, Ars E, Lozano JJ,
Villavicencio H, Ribal MJ and Alcaraz A: DNA microarray expression
profiling of bladder cancer allows identification of noninvasive
diagnostic markers. J Urol. 182:741–748. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Smyth GK: Limma: Linear models for
microarray dataBioinform Comput Biol Sol Using R Bioconduct.
Springer; pp. 397–420. 2005
|
|
12
|
Hardcastle TJ: Generalized empirical
Bayesian methods for discovery of differential data in
high-throughput biology. Bioinformatics. 32:195–202.
2016.PubMed/NCBI
|
|
13
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stelzl U, Worm U, Lalowski M, Haenig C,
Brembeck FH, Goehler H, Stroedicke M, Zenkner M, Schoenherr A,
Koeppen S, et al: A human protein-protein interaction network: A
resource for annotating the proteome. Cell. 122:957–968. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Von Mering C, Huynen M, Jaeggi D, Schmidt
S, Bork P and Snel B: STRING: A database of predicted functional
associations between proteins. Nucleic Acids Res. 31:258–261. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Szklarczyk D, Franceschini A, Kuhn M,
Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork
P, et al: The STRING database in 2011: Functional interaction
networks of proteins, globally integrated and scored. Nucleic Acids
Res. 39:(Database Issue). D561–D568. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bandettini WP, Kellman P, Mancini C,
Booker OJ, Vasu S, Leung SW, Wilson JR, Shanbhag SM, Chen MY and
Arai AE: MultiContrast delayed enhancement (MCODE) improves
detection of subendocardial myocardial infarction by late
gadolinium enhancement cardiovascular magnetic resonance: A
clinical validation study. J Cardiovasc Magn Reson. 14:832012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dai QS, He HC, Cai C, Chen JH, Han ZD, Qin
GQ, Liang YX and Zhong WD: Multicenter case-control study of the
relationship between smoking and bladder cancer in China. Zhonghua
Yi Xue Za Zhi. 91:2407–2410. 2011.(In Chinese). PubMed/NCBI
|
|
19
|
Boccaccio C and Medico E: Cancer and blood
coagulation. Cell Mol Life Sci. 63:1024–1027. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gay LJ and Felding-Habermann B:
Contribution of platelets to tumour metastasis. Nat Rev Cancer.
11:123–134. 2011.Falanga A, Marchetti M and Vignoli A: Coagulation
and cancer: Biological and clinical aspects. J Thromb Haemost 11:
223–233, 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao M, Li Z and Qu H: An evidence-based
knowledgebase of metastasis suppressors to identify key pathways
relevant to cancer metastasis. Sci Rep. 5:154782015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
MacLachlan TK, Sang N and Giordano A:
Cyclins, cyclin-dependent kinases and cdk inhibitors: Implications
in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr.
5:127–156. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dalbagni G, Presti J, Reuter V, Fair WR
and Cordon-Cardo C: Genetic alterations in bladder cancer. Lancet.
342:469–471. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cote RJ, Dunn MD, Chatterjee SJ, Stein JP,
Shi SR, Tran QC, Hu SX, Xu HJ, Groshen S, Taylor CR, et al:
Elevated and absent pRb expression is associated with bladder
cancer progression and has cooperative effects with p53. Cancer
Res. 58:1090–1094. 1998.PubMed/NCBI
|
|
26
|
Cordon-Cardo C, Wartinger D, Petrylak D,
Dalbagni G, Fair WR, Fuks Z and Reuter VE: Altered expression of
the retinoblastoma gene product: Prognostic indicator in bladder
cancer. J Natl Cancer Inst. 84:1251–1256. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bossis G, Malnou CE, Farras R,
Andermarcher E, Hipskind R, Rodriguez M, Schmidt D, Muller S,
Jariel-Encontre I and Piechaczyk M: Down-regulation of c-Fos/c-Jun
AP-1 dimer activity by sumoylation. Mol Cell Biol. 25:6964–6979.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hess J, Angel P and Schorpp-Kistner M:
AP-1 subunits: Quarrel and harmony among siblings. J Cell Sci.
117:5965–5973. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ye N, Ding Y, Wild C, Shen Q and Zhou J:
Small molecule inhibitors targeting activator protein 1 (AP-1). J
Med Chem. 57:6930–6948. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Durchdewald M, Angel P and Hess J: The
transcription factor Fos: A Janus-type regulator in health and
disease. Histol Histopathol. 24:1451–1461. 2009.PubMed/NCBI
|
|
31
|
Yao HQ, Peng Y, Zhong ZZ, He HX and Li ZH:
Association of the expressions of platelet-derived growth factor
receptor and c-Fos with the biological characteristics of bladder
cancer. Di Yi Jun Yi Da Xue Xue Bao. 24:177–179. 2004.PubMed/NCBI
|
|
32
|
Lan G, Yang L, Xie X, Peng L and Wang Y:
MicroRNA-490-5p is a novel tumor suppressor targeting c-FOS in
human bladder cancer. Arch Med Sci. 11:561–569. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vleugel MM, Greijer AE, Bos R, van der
Wall E and van Diest PJ: c-Jun activation is associated with
proliferation and angiogenesis in invasive breast cancer. Human
Pathol. 37:668–674. 2006. View Article : Google Scholar
|
|
34
|
Eferl R, Ricci R, Kenner L, Zenz R, David
JP, Rath M and Wagner EF: Liver tumor development. c-Jun
antagonizes the proapoptotic activity of p53. Cell. 112:181–192.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huhe M, Liu S, Zhang Y, Zhang Z and Chen
Z: Expression levels of transcription factors c-Fos and c-Jun and
transmembrane protein HAb18G/CD147 in urothelial carcinoma of the
bladder. Mol Med Rep. 15:2991–3000. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hunter T and Pines J: Cyclins and cancer.
II: Cyclin D and CDK inhibitors come of age. Cell. 79:573–582.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhong Z, Yeow WS, Zou C, Wassell R, Wang
C, Pestell RG, Quong JN and Quong AA: Cyclin D1/cyclin-dependent
kinase 4 interacts with filamin A and affects the migration and
invasion potential of breast cancer cells. Cancer Res.
70:2105–2114. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Feakins RM, Nickols CD, Bidd H and Walton
SJ: Abnormal expression of pRb, p16, and cyclin D1 in gastric
adenocarcinoma and its lymph node metastases: Relationship with
pathological features and survival. Hum Pathol. 34:1276–1282. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jovanovic IP, Radosavljevic GD,
Simovic-Markovic BJ, Stojanovic SP, Stefanovic SM, Pejnovic NN and
Arsenijevic NN: Clinical significance of Cyclin D1, FGF3 and p21
protein expression in laryngeal squamous cell carcinoma. J BUON.
19:944–952. 2014.PubMed/NCBI
|
|
40
|
Xu S, Gu G, Ni Q, Li N, Yu K, Li X and Liu
C: The expression of AEG-1 and Cyclin D1 in human bladder
urothelial carcinoma and their clinicopathological significance.
Int J Clin Exp Med. 8:21222–21228. 2015.PubMed/NCBI
|
|
41
|
Mao Q, Li Y, Zheng X, Yang K, Shen H, Qin
J, Bai Y, Kong D, Jia X and Xie L: Up-regulation of E-cadherin by
small activating RNA inhibits cell invasion and migration in 5637
human bladder cancer cells. Biochem Biophys Res Commun.
375:566–570. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cavallaro U, Schaffhauser B and
Christofori G: Cadherins and the tumour progression: Is it all in a
switch? Cancer Lett. 176:123–128. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mialhe A, Levacher G, Champelovier P,
Martel V, Serres M, Knudsen K and Seigneurin D: Expression of E-,
P-, n-cadherins and catenins in human bladder carcinoma cell lines.
J Urol. 164:826–835. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wheelock MJ, Shintani Y, Maeda M, Fukumoto
Y and Johnson KR: Cadherin switching. J Cell Sci. 121:727–735.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Molinari M: Cell cycle checkpoints and
their inactivation in human cancer. Cell Prolif. 33:261–274. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hochegger H, Takeda S and Hunt T:
Cyclin-dependent kinases and cell-cycle transitions: Does one fit
all? Nat Rev Mol Cell Biol. 9:910–916. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Möröy T and Geisen C: Cyclin E. Int J
Bioch Cell Biol. 36:1424–1439. 2004. View Article : Google Scholar
|
|
48
|
Sutherland RL and Musgrove EA: Cyclins and
breast cancer. J Mammary Gland Biol Neoplasia. 9:95–104. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lee MH and Yang HY: Regulators of G1
cyclin-dependent kinases and cancers. Cancer Metast Rev.
22:435–449. 2003. View Article : Google Scholar
|
|
50
|
Sávio AL, da Silva GN and Salvadori DM:
Inhibition of bladder cancer cell proliferation by allyl
isothiocyanate (mustard essential oil). Mutat Res. 771:29–35. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kim SJ, Nakayama S, Miyoshi Y, Taguchi T,
Tamaki Y, Matsushima T, Torikoshi Y, Tanaka S, Yoshida T, Ishihara
H and Noguchi S: Determination of the specific activity of CDK1 and
CDK2 as a novel prognostic indicator for early breast cancer. Ann
Oncol. 19:68–72. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Leonardi E, Girlando S, Serio G, Mauri FA,
Perrone G, Scampini S, Dalla Palma P and Barbareschi M: PCNA and
Ki67 expression in breast carcinoma: Correlations with clinical and
biological variables. J Clin Pathol. 45:416–419. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Al-Dhaheri WS, Hassouna I, Al-Salam S and
Karam SM: Characterization of breast cancer progression in the rat.
Ann N Y Acad Sci. 1138:121–131. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bravo R, Frank R, Blundell PA and
Macdonald-Bravo H: Cyclin/PCNA is the auxiliary protein of DNA
polymerase. Nature. 326:515–517. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Nagase Y, Moriyama N, Kurimoto S, Tajima
A, Higashihara E and Aso Y: Histochemical expression of
proliferating cell nuclear antigen (PCNA) for pre and post
chemotherapeutic bladder cancer. Nihon Hinyokika Gakkai Zasshi.
86:985–990. 1995.(In Japanese). PubMed/NCBI
|
|
56
|
Inagaki T, Ebisuno S, Uekado Y, Hirano A,
Hiroi A, Shinka T and Ohkawa T: PCNA and p53 in urinary bladder
cancer: Correlation with histological findings and prognosis. Int J
Urol. 4:172–177. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Malkas LH, Herbert BS, Abdel-Aziz W,
Dobrolecki LE, Liu Y, Agarwal B, Hoelz D, Badve S, Schnaper L,
Arnold RJ, et al: A cancer-associated PCNA expressed in breast
cancer has implications as a potential biomarker. Proc Natl Acad
Sci USA. 103:pp. 19472–19477. 2006; View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Koren R, Kugel V, Dekel Y, Weissman Y,
Livne PM and Gal R: Human DNA topoisomerase-IIalpha expression as a
prognostic factor for transitional cell carcinoma of the urinary
bladder. BJU Int. 91:489–492. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Mu XC, Tran TA, Ross JS and Carlson JA:
Topoisomerase II-alpha expression in melanocytic nevi and malignant
melanoma. J Cutan Pathol. 27:242–248. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Holden JA and Townsend JJ: DNA
topoisomerase II-alpha as a proliferation marker in astrocytic
neoplasms of the central nervous system: Correlation with MIB1
expression and patient survival. Mod Pathol. 12:1094–1100.
1999.PubMed/NCBI
|
|
61
|
Costa MJ, Hansen CL, Holden JA and Guinee
D Jr: Topoisomerase II alpha: Prognostic predictor and cell cycle
marker in surface epithelial neoplasms of the ovary and peritoneum.
Int J Gynecol Pathol. 19:248–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Dingemans AM, Witlox MA, Stallaert RA, van
der Valk P, Postmus PE and Giaccone G: Expression of DNA
topoisomerase IIalpha and topoisomerase IIbeta genes predicts
survival and response to chemotherapy in patients with small cell
lung cancer. Clin Cancer Res. 5:2048–2058. 1999.PubMed/NCBI
|
|
63
|
Depowski PL, Rosenthal SI, Brien TP,
Stylos S, Johnson RL and Ross JS: Topoisomerase IIalpha expression
in breast cancer: Correlation with outcome variables. Mod Pathol.
13:542–547. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Koren R, Kugel V, Dekel Y, Weissman Y,
Livne PM and Gal R: Human DNA topoisomerase-IIalpha expression as a
prognostic factor for transitional cell carcinoma of the urinary
bladder. BJU Int. 91:489–492. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Simon R, Atefy R, Wagner U, Forster T,
Fijan A, Bruderer J, Wilber K, Mihatsch MJ, Gasser T and Sauter G:
HER-2 and TOP2A coamplification in urinary bladder cancer. Int J
Cancer. 107:764–772. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Lindén M, Segersten U, Runeson M, Wester
K, Busch C, Pettersson U, Lind SB and Malmström PU: Tumour
expression of bladder cancer-associated urinary proteins. BJU Int.
112:407–415. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Manning BD and Cantley LC: AKT/PKB
signaling: Navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Song G, Ouyang G and Bao S: The activation
of Akt/PKB signaling pathway and cell survival. J Cell Mol Med.
9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Nicholson KM and Anderson NG: The protein
kinase B/Akt signalling pathway in human malignancy. Cell Signal.
14:381–395. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Yousif NG: Fibronectin promotes migration
and invasion of ovarian cancer cells through up-regulation of
FAK-PI3K/Akt pathway. Cell Biol Int. 38:85–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Chen Y, Wang Z, Chang P, Xiang L, Pan F,
Li J, Jiang J, Zou L, Yang L, Bian Z and Liang H: The effect of
focal adhesion kinase gene silencing on 5-fluorouracil
chemosensitivity involves an Akt/NF-kappaB signling pathway in
colorectal carcrinomas. Int J Cancer. 127:195–206. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Xu ZZ, Xia ZG, Wang AH, Wang WF, Liu ZY,
Chen LY and Li JM: Activation of the PI3K/AKT/mTOR pathway in
diffuse large B cell lymphoma: Clinical significance and inhibitory
effect of rituximab. Ann Hematol. 92:1351–1358. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ripka S, Neesse A, Riedel J, Bug E, Aigner
A, Poulsom R, Fulda S, Neoptolemos J, Greenhalf W, Barth P, et al:
CUX1: Target of Akt signaling ang mediator of resisitance to
apoptosis in pancreatic cancer. Gut. 59:1101–1110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Cumberbatch M, Tang X, Beran G, Eckersley
S, Wang X, Ellston RP, Dearden S, Cosulich S, Smith PD, Behrens C,
et al: Identification of a subset of human non-small cell lung
cancer patients with high PI3Kβ and low PTEN expression, more
prevalent in squamous cell carcinoma. Clin Cancer Res. 11:595–603.
2014. View Article : Google Scholar
|
|
75
|
Xie X, Tang B, Zhou J, Gao Q and Zhang P:
Inhibition of the PI3K/Akt pathway increases the chemosensitivity
of gastric cancer to vincristine. Oncol Rep. 30:773–782. 2013.
View Article : Google Scholar : PubMed/NCBI
|
